Autoimmune diseases
a global public
Healthcare Issue
with unmet medical needs

The number of patients affected by autoimmune diseases is increasing worldwide. The treatment of autoimmune diseases is costly and  a serious concern to healthcare system.

Kinoid® technology:
An innovative
therapeutic Approach

Our Kinoid®  technology is an alternative to monoclonal antibodies.

Our ambition:
to develop accessible treatments

Our goal is to provide patients with less costly, more convenient and safe treatments, without hospitalization.

About Neovacs

Neovacs is a French biotech company focused on the development of Kinoids®, therapeutic vaccines for the treatment of autoimmune diseases.

Discover our Kinoids®

Therapeutic vaccines to treat several chronic diseases:

IFN Kinoide
and LUPUS

Lupus is a chronic autoimmune disease, which can affect several organs.  phase IIb clinical study in US, EU, Asia and South-America completed.

show more

IL-4 /IL-13 KINOID AND ALLERGIES

Neovacs’ technology has the potential to treat patients suffering from environmental and food allergies.

show more
Image Alt Text

Applying vaccine technology to treat chronic diseases

More details

Why should you invest in Neovacs ?

go to the investors section

News

The Lancet Rheumatology: Lupus low disease...

THE LANCET

Entreprise du jour: Néovacs annonce les...

Entretien avec Miguel Sieler, président directeur général de Néovacs. – Intégrale Bourse,...

imagespt99l2hs

Tête à tête de la finance

ITW de Miguel Sieler, directeur Général de Néovacs

bouriser (2)

Des résultats cliniques de bonne qualité...

La biotech a communiqué des résultats de phase II b qui étaient très attendus dans l’indication du...

investir1

Follow us on Twitter